Bookmark and Share

Siemens Healthineers

511 Benedict Avenue
Tarrytown,  NY  10591

United States
http://usa.siemens.com/Healthineers
  • Booth: 2101

Siemens Healthineers is committed to becoming the trusted partner of healthcare providers worldwide, enabling them to improve patient outcomes while reducing costs. Driven by our long legacy of engineering excellence and our pioneering approach to developing the latest advancements, we are a global leader in medical imaging, laboratory diagnostics, clinical IT, and services. usa.siemens.com/Healthineers


 Press Releases

  • Siemens Healthineers Unveils Game-changing Atellica Solution at AACC 2016

     

    • Patented, bi-directional magnetic sample transport technology1 is 10 times faster than conventional conveyors

    • Immunoassay analyzer delivers the industry’s highest productivity per square meter2—more than 400 tests per hour3

    • Multi-camera vision system and intelligent sample routing enable independent control over every sample from routine to STATs1

    • Scalable up to 10 components and more than 300 customizable configurations1 can be used as a standalone system or connected to automation1

    • Can handle more than 30 sample container types including pediatric and special containers

       

      Today Siemens Healthineers unveiled the Atellica™ Solution,1 a highly flexible immunoassay and clinical chemistry solution featuring patented bi-directional magnetic sample-transport technology that is 10 times faster than conventional conveyors.1 The unveiling occurred during the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia, July 31 – August 4 (booth 2101).

       

      “We engineered the Atellica Solution1 based on our customers’ needs and extensive research of market trends,” said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers. “The result is a game-changer that delivers control and simplicity, so our customers can focus on driving better business and clinical outcomes and spend less time managing operations.”

                                                                                        

      In addition to the speed afforded by the Atellica Magline™ Transport technology,1 the Atellica Solution1 offers a multi-camera vision system1 and intelligent sample routing1 for independent control over every sample from routines to STATs.

       

      The Atellica Solution1 provides unprecedented flexibility to adapt to growing testing needs and space constraints. The solution can be used as a stand-alone system, is scalable up to 10 components and can be combined into more than 300 customizable configurations,1 including L-shaped, U-shaped, and linear formations. It can also be connected to Aptio® Automation for a comprehensive multidisciplinary solution.1 The solution can handle more than 30 sample container types including pediatric and special containers.

       

      Further, the same reagents can be used across configurations and locations, simplifying laboratory operations, streamlining inventory control, and enabling consistent testing results. Additionally, a single immunoassay analyzer processes more than 400 tests per hour,3 delivering the highest productivity per square meter in the industry.2

       

      Other benefits of the Atellica Solution1 include remote-access monitoring and control1 to maximize uptime, and a broad, expanding assay menu1 using proven detection technologies.

       

      The Atellica Solution1 is the first in a new line of Atellica products engineered by Siemens Healthineers and further innovations are in the R&D pipeline.

       

      1 Products are under FDA review.  Not available for sale.  Any features listed are part of the development design goals.  Future availability cannot be guaranteed.

      2 Versus leading IVD market competitors.

      3 Dependent upon test mix.

       

      For further information on Siemens Healthineers, please see www.healthcare.siemens.com.

      For further information on the Atellica Solution and other Siemens Healthineers products being exhibited at AACC, please see www.siemens.com/aacc.

       

      Contact for journalists

      Kimberly Nissen, Siemens Healthineers

      Phone: +1 610.448.6355; E-mail: kimberly.nissen@siemens.com


      Follow us on Twitter at: www.twitter.com/SiemensHealth

       

    Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world’s largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of gas and steam turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2015, which ended on September 30, 2015, Siemens generated revenue of €75.6 billion and net income of €7.4 billion. At the end of September 2015, the company had around 348,000 employees worldwide. Further information is available on the Internet at www.siemens.com

  • Siemens Healthcare Diagnostics Inc. Receives Emergency Use Authorization from FDA for its VERSANT® Zika RNA 1.0 Assay (kPCR) Kit

     

    The U.S. Food and Drug Administration (FDA) has granted Siemens Healthcare Diagnostics Inc. (Siemens) an Emergency Use Authorization (EUA) for its real-time PCR Zika Virus assay, the VERSANT® Zika RNA 1.0 Assay (kPCR) Kit.  With respect to Zika in vitro diagnostic tests, FDA has been authorized to issue EUAs to allow for use of unapproved medical products or unapproved uses of approved medical products when, among other circumstances, there are no adequate, approved, and available alternatives and certain additional criteria are met.[i]

     

    “The FDA’s emergency use authorization of the VERSANT® Zika RNA 1.0 Assay (kPCR) Kit from Siemens can lead us one step closer to stopping the spread of the Zika virus,” says Fernando Beils, Vice President, Head of Molecular Diagnostics, Siemens . “Being able to quickly diagnose patients will help physicians to more efficiently manage those affected.”

     

    The VERSANT® Zika RNA 1.0 Assay (kPCR) Kit is capable of detecting the presence of Zika virus, which can be an earlier indicator of Zika virus infection than anti-Zika antibodies. The molecular test is validated for plasma, serum, and urine (collected alongside a patient-matched serum or plasma specimen) from individuals meeting CDC Zika virus clinical criteria and/or CDC Zika virus epidemiological criteria, and is designed to run on the Siemens VERSANT® kPCR Sample Prep automated platform, along with several commercially available thermal cyclers. The assay must be run by laboratories in the United States that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests, or by similarly qualified non-U.S. laboratories. The VERSANT® Zika RNA 1.0 Assay (kPCR) Kit has not been FDA cleared or approved and is only authorized for use for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection.

     

    For more information on the FDA’s EUA for Siemens’ VERSANT Zika RNA 1.0 Assay (kPCR), visit: www.fda.gov/MedicalDevices/Safety/EmergencySituations/ucm161496.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery#zika

     

     

     

    Contact for journalists

    Lance Longwell, Siemens Healthineers

    Phone: 610-448-6341; E-mail: Lance.Longwell@siemens.com

     

    Follow us on Twitter at: www.twitter.com/SiemensHealth

     

     

    Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world’s largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of gas and steam turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2015, which ended on September 30, 2015, Siemens generated revenue of €75.6 billion and net income of €7.4 billion. At the end of September 2015, the company had around 348,000 employees worldwide. Further information is available on the Internet at www.siemens.com.

     

     

  • Siemens Launches New Mid-volume Coagulation Analyzer and Celebrates Expanded Portfolio 

    • Enables hemostasis laboratories to standardize testing results across multiple
      Sysmex CS and CA hemostasis systems

    • Enhances efficiency via a wide optical spectrum, which allows clotting, chromogenic, immunologic and aggregation1 testing capabilities on a single platform
       

    Today, Siemens Healthineers Laboratory Diagnostics business launched the Sysmex CS-2500 System—a mid-volume, fully-automated coagulation analyzer with smartly-designed PSI technology—in major markets including the U.S. Together with Lab Alliance of Central New York, the first U.S. customer to install the high-volume Sysmex CS-5100 System, the company celebrated the availability of its new Sysmex CS Hemostasis System portfolio in the U.S.

    The launch of the new Sysmex CS-2500 System will enable mid-volume laboratories to leverage globally-proven PSI technology, while providing regional reference laboratories and integrated delivery networks (IDNs) with the ability to standardize testing results across multiple Sysmex CS and CA hemostasis systems.    

    “Labs today are challenged to increase their output without sacrificing the accuracy or reliability of their results. The Sysmex CS Systems are the answer to this demand,” said Franz Walt, President, Laboratory Diagnostics, Siemens Healthineers. “The increased operational efficiency and uninterrupted workflow delivered by the Sysmex CS-5100 and CS-2500 Systems provide our customers with the confidence, consistency and increased capacity they need to deliver timely and accurate hemostasis test results.”

    In most markets, the Sysmex CS-2500 System features simultaneous multiwavelength scanning and proven PSI technologies including primary-tube sample-volume checks, clog detection, assay-based preanalytical sample-quality checks for hemolysis, icterus and lipemia (HIL) interference;1 automated mixing studies;1 automated platelet aggregation;1 and clot waveform analysis (CWA)2 —enabling labs to raise the quality of test results, achieve cost-effective method consolidation, simplify operations, and increase diagnostic confidence.

    The new system enhances efficiency via a wide optical spectrum, which allows clotting, chromogenic, immunologic and aggregation1 testing capabilities on a single platform. With an onboard capacity of up to 3,000 tests3 and up to 40 reagents, the Sysmex CS-2500 System delivers extended walkaway time to streamline workflow.

    Anne Chamberlain, Hematology Manager at Laboratory Alliance of Central New York, remarked, “The Sysmex CS Systems and the services offered by Siemens Healthineers are the perfect fit for our laboratory and laboratory networks similar to ours. The intuitive system software, readily accessible patient analysis data and result traceability simplifies our operations. This enables our lab to deliver quality test results, which positively impacts patient care for our clients.”

    To help labs ensure consistency and improve productivity, the systems use the same reagents, controls and calibrators as other coagulation analyzers offered by Siemens Healthineers.

     

    For more information about the Sysmex CS-2500 System, please visit: http://www.healthcare.siemens.com/hemostasis/systems/sysmex-cs-2500-system

     

    1. The features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

    2. For Research Use Only. Not for use in diagnostic procedures.

    3. Based on internal validation data from Sysmex Corporation.

     

    Contact for journalists:

    Kimberly Nissen, Siemens Healthineers

    Phone: +1 (610) 448-6355, Email: kimberly.nissen@siemens.com

     

    Follow us on Twitter at www.twitter.com/siemenshealth.

     

    The products/features mentioned here are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Further details are available from the local Siemens organizations.

     

    Siemens AG (Berlin and Munich) is a global technology powerhouse that has stood for engineering excellence, innovation, quality, reliability and internationality for more than 165 years. The company is active in more than 200 countries, focusing on the areas of electrification, automation and digitalization. One of the world’s largest producers of energy-efficient, resource-saving technologies, Siemens is No. 1 in offshore wind turbine construction, a leading supplier of gas and steam turbines for power generation, a major provider of power transmission solutions and a pioneer in infrastructure solutions as well as automation, drive and software solutions for industry. The company is also a leading provider of medical imaging equipment – such as computed tomography and magnetic resonance imaging systems – and a leader in laboratory diagnostics as well as clinical IT. In fiscal 2015, which ended on September 30, 2015, Siemens generated revenue of €75.6 billion and net income of €7.4 billion. At the end of September 2015, the company had around 348,000 employees worldwide. Further information is available on the Internet at www.siemens.com.


 Products

  • ADVIA Centaur® Active-B12 Assay
    The ADVIA Centaur® Active-B12 assay is an innovative new method for assessing vitamin B12 status. The active-B12 assay measures the biologically active form of vitamin B12, delivering confidence with improved sensitivity and specificity over current laboratory methods....
       

  • The ADVIA Centaur® Active-B12 assay is an innovative new method for assessing vitamin B12 status. The active-B12 assay measures holoTC in the blood—the only form of vitamin B12 that is taken up and used by cells of the body—delivering confidence with improved sensitivity and specificity over current laboratory methods. Numerous studies support that it is an optimal early marker of vitamin B12 deficiency. Incorporate the new active-B12 assay and complete your anemia testing panel on one trusted platform.

    SAMPLE: *Product availability varies by country.*Not available for sale in the U.S.

  • ADVIA Centaur® Anti-CCP IgG Assay
    The ADVIA Centaur® Anti-CCP IgG assay is used as an aid in the diagnosis of rheumatoid arthritis (RA). Tests for cyclic citrullinated peptide antibodies (anti-CCP) are increasingly being utilized alongside RF for early RA diagnosis, and have recently been incorporated into the 2010 classification criteria for RA....
       

  • The ADVIA Centaur® Anti-CCP IgG assay is used as an aid in the diagnosis of rheumatoid arthritis (RA). Tests for cyclic citrullinated peptide antibodies (anti-CCP) are increasingly being utilized alongside RF for early RA diagnosis, and have recently been incorporated into the 2010 classification criteria for RA. RF alone lacks the level of specificity that the second-generation anti-CCP test offers. Although estimates vary, generally the RF test is 68–81% sensitive and 60–85% specific, whereas the anti-CCP test is about 41–89% sensitive and 89–99% specific. The addition of the anti-CCP assay will allow you to achieve a more accurate RA diagnosis.

    *Product availability varies by country. Not available for sale in the U.S.

  • Aptio® Automation
    Aptio® Automation combines intelligent technologies with Siemens workflow expertise to deliver flexible solutions that advance laboratory productivity. Aptio supports connectivity to more diagnostic analyzers, preanalytical modules, and process management tools to simplify multidisciplinary testing, control operations, and drive better outcomes....
         

  • Aptio® Automation combines intelligent technologies with Siemens workflow expertise to deliver flexible solutions that advance laboratory productivity. Labs can leverage enhancements introduced in 2016--including more diagnostic analyzers, pre-analytical modules, and process management tools —to simplify multidisciplinary testing. Visit the leader in total lab automation at booth #2101 to learn how the data-driven simulations, optimization modeling, and best practices of an experienced automation partner can turn lab testing complexity into efficiency with our comprehensive diagnostics portfolio and proven project management. Highly adaptable, needs-based Aptio Automation solutions will enable you to accelerate sample processing, achieve consistent turnaround times, and proactively control your operations for better patient outcomes.

     

  • Dimension® Integrated Systems Tacrolimus Assay
    The new Dimension® Tacrolimus assay provides confidence in test results for complete care of transplant patients, including tacrolimus minimization regimens. With no manual sample-pretreatment steps required, tacrolimus testing can be added to your lab’s routine daily workload....
       

  • The Dimension® Tacrolimus assay eliminates manual sample-pretreatment steps to deliver tangible clinical and analytical benefits. Excellent precision across the entire assay range enables management of transplant patients at any phase of immunosuppressant drug (ISD) therapy and at any therapeutic target level. Since no manual sample-pretreatment steps are required, tacrolimus testing can be added to the routine daily workload of any laboratory, eliminating the need for specialized equipment and freeing up valuable personnel. When survival is on the line, the quality of tacrolimus results cannot be compromised. The Dimension Tacrolimus assay provides reliable results for targeted tacrolimus patient monitoring.

    *Product availability varies by country.

  • IMMULITE® 2000 TSI Assay
    Detecting TSI in the blood is a powerful diagnostic tool for the differential diagnosis of Graves’ disease (GD). The IMMULITE® 2000 TSI assay is the first automated TSI assay available, potentially making the differential diagnosis of GD faster and easier. This could lead to faster patient diagnosis and treatment. ...
       

  • Detecting the presence of TSI in the blood is a powerful diagnostic tool for the differential diagnosis of Graves’ disease (GD). Thyroid receptor antibody (TRAb) assays detect both thyroid-blocking and -stimulating antibodies. However, blocking antibodies are present in other thyroid conditions such as hypothyroidism. The IMMULITE® 2000 TSI assay is designed to detect only thyroid-stimulating antibodies, the specific cause of GD pathology. The use of this assay can potentially make the differential diagnosis of GD faster and easier. This could lead to faster patient diagnosis and treatment, and allow patients to be monitored more efficiently. The IMMULITE 2000® TSI assay is the first automated TSI assay available.

    *Product availability varies by country.

  • Sysmex CS-2500 System
    The Sysmex® CS-2500 System— now available globally including the U.S.—offers mid-volume and multisite hemostasis labs smartly designed technologies for improved efficiency, exceptional accuracy, and reliable first-run results. Equipped with next-generation PSI™ technologies, the system takes hemostasis testing to the next level....
       

  • The Sysmex CS-2500 System offers mid-volume and multisite hemostasis labs smartly designed technologies, including:

    Assay-based preanalytical checks for detection of hemolysis, icterus, and lipemia interference;* underfilled primary-sample tubes; and clogs to minimize retesting Automated platelet aggregation,*automated mixing studies,* and clot waveform analysis for cost-effective consolidation A wide spectrum of testing methodologies and sophisticated software to simplify lab operations Uninterrupted workflow delivered in a compact, affordable footprintTrue lab-to-lab consistency for confident multisite patient monitoring

     

  • Sysmex® CS-5100 System
    The Sysmex® CS-5100 System—now available in the U.S.—offers high-volume and multisite labs smartly designed PSI™ technology and automation connectivity for streamlined workflow and high-quality test results on the first run. Simultaneous, multiwavelength PSI technology helps labs to identify and manage unsuitable test specimens prior to analysis....
         

  • The Sysmex® CS-5100 System—now available in the U.S.—offers high-volume and multisite labs smartly designed PSI™ technology and flexible automation connectivity for streamlined workflow and high-quality test results on the first run. Smartly designed PSI technology checks primary-tube sample volumes to identify and automatically manage problematic test samples prior to analysis.

    • Primary-tube sample-volume check identifies potential inaccuracies caused by improper sample collection.
    • System accepts or flags sample results based upon an incorrect tube fill volume according to user-programmable configuration settings.
    • System performs simultaneous multiwavelength scanning of clotting reactions at 340, 405, 575, 660, and 800 nm.

    Please contact your local Siemens organization for further details. Sysmex is a trademark of Sysmex Corporation.

  • RAPIDComm® 6.0 Data Management System
    The RAPIDComm® Data Management System gives you freedom to control your environment and confidence and control over all the parts of your POC Ecosystem™. The RAPIDComm system enables centralized management of point-of-care testing through a single, customizable interface. It helps streamline workflow, reduce costs, and improve patient care....
         

  • RAPIDComm® 6.0 Data Management System software gives you confidence and control over all the parts of your POC Ecosystem™ and the freedom to control your environment.

    The RAPIDComm Data Management System enables centralized management of point-of-care testing through a single, customizable interface. It helps streamline workflow, reduce costs, and improve patient care, regardless of your program’s size or location. It is a key enabler for POCT coordinators, helping them to establish and maintain a healthy ecosystem through which testing efficiency is maximized, clinical workflow is improved, compliance is adhered to, and costs are efficiently managed.

    Product availability varies by country.

  • Emit® II Plus Buprenorphine Assay
    The Emit® II Plus Buprenorphine assay detects buprenorphine and norbuprenorphine in human urine and gives a positive result if present at concentrations equal to or greater than the cutoff. As part of the complete Syva® DAT offering, it provides results in minutes for optimized workflow....
       

  • The Emit® II Plus Buprenorphine assay detects buprenorphine and norbuprenorphine in human urine and gives a positive result if present at concentrations equal to or greater than the cutoff. Buprenorphine is used as a substitution drug for opioid addiction treatment but has a high potential for abuse and addiction. As part of the complete Syva® DAT offering, it provides results in minutes for optimized workflow. Syva Emit reagents offer the flexibility and capacity to meet all your drug-monitoring needs.

    *Product availability varies by country.

 

  •  
    • AACC Annual Scientific Meeting & Clinical Lab Expo Management
    • SPARGO, Inc.
    • Toll Free (800) 564-4220
    • Phone:  (703) 631-6200
    • Fax (703) 563-2691
    • Email:  aaccexhibits@spargoinc.com
  •